De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Neuren Pharmaceuticals Toekomstige groei
Future criteriumcontroles 2/6
Neuren Pharmaceuticals zal naar verwachting groeien in winst en omzet met respectievelijk 4.6% en 3.1% per jaar. De winst per aandeel zal naar verwachting groeien met 4.9% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 24.2% zijn.
Belangrijke informatie
4.6%
Groei van de winst
4.9%
Groei van de winst per aandeel
Pharmaceuticals winstgroei | 55.3% |
Inkomstengroei | 3.1% |
Toekomstig rendement op eigen vermogen | 24.2% |
Dekking van analisten | Good |
Laatst bijgewerkt | 09 Sep 2024 |
Recente toekomstige groei-updates
Recent updates
Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Aug 29Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now
Aug 14Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today
May 31Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely
May 03An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued
Apr 01Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically
Mar 05Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors
Mar 02Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors
Dec 18Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues
Sep 02Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Aug 31This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year
Mar 03Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business
Jan 07We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
Sep 06Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth
May 31We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn
Feb 03Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation
Aug 06We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
May 05Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)
Feb 19Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?
Jan 04Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 187 | 118 | 100 | 80 | 5 |
12/31/2025 | 160 | 104 | 123 | 114 | 6 |
12/31/2024 | 123 | 80 | -28 | 37 | 6 |
6/30/2024 | 193 | 117 | 119 | 120 | N/A |
3/31/2024 | 213 | 137 | 152 | 152 | N/A |
12/31/2023 | 232 | 157 | 185 | 185 | N/A |
9/30/2023 | 155 | 106 | 120 | 120 | N/A |
6/30/2023 | 78 | 55 | 54 | 54 | N/A |
3/31/2023 | 47 | 28 | 29 | 29 | N/A |
12/31/2022 | 15 | 0 | 4 | 4 | N/A |
9/30/2022 | 9 | -3 | -3 | -3 | N/A |
6/30/2022 | 3 | -7 | -10 | -10 | N/A |
3/31/2022 | 3 | -7 | -10 | -10 | N/A |
12/31/2021 | 3 | -8 | -10 | -10 | N/A |
9/30/2021 | 2 | -10 | -10 | -10 | N/A |
6/30/2021 | 1 | -12 | -9 | -9 | N/A |
3/31/2021 | 1 | -11 | -9 | -9 | N/A |
12/31/2020 | 1 | -9 | -8 | -8 | N/A |
9/30/2020 | 1 | -8 | -9 | -9 | N/A |
6/30/2020 | 0 | -8 | -9 | -9 | N/A |
3/31/2020 | 0 | -9 | -10 | -10 | N/A |
12/31/2019 | 0 | -11 | -12 | -12 | N/A |
9/30/2019 | 7 | -6 | -5 | -5 | N/A |
6/30/2019 | 14 | -1 | 2 | 2 | N/A |
3/31/2019 | 14 | 1 | 4 | 4 | N/A |
12/31/2018 | 14 | 3 | 6 | 6 | N/A |
9/30/2018 | 7 | 3 | 0 | 0 | N/A |
6/30/2018 | 1 | 3 | -6 | -6 | N/A |
3/31/2018 | 1 | 3 | N/A | -6 | N/A |
12/31/2017 | 1 | 3 | N/A | -6 | N/A |
9/30/2017 | 2 | -2 | N/A | -7 | N/A |
6/30/2017 | 3 | -8 | N/A | -8 | N/A |
3/31/2017 | 3 | -10 | N/A | -10 | N/A |
12/31/2016 | 3 | -12 | N/A | -12 | N/A |
9/30/2016 | 2 | -14 | N/A | -14 | N/A |
6/30/2016 | 0 | -15 | N/A | -17 | N/A |
3/31/2016 | 1 | -14 | N/A | -15 | N/A |
12/31/2015 | 2 | -13 | N/A | -13 | N/A |
9/30/2015 | 2 | -11 | N/A | -11 | N/A |
6/30/2015 | 3 | -9 | N/A | -8 | N/A |
3/31/2015 | 3 | -9 | N/A | -7 | N/A |
12/31/2014 | 3 | -8 | N/A | -6 | N/A |
9/30/2014 | 3 | -10 | N/A | -7 | N/A |
6/30/2014 | 3 | -12 | N/A | -7 | N/A |
3/31/2014 | 4 | -11 | N/A | -7 | N/A |
12/31/2013 | 5 | -10 | N/A | -7 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei NEU ( 4.6% per jaar) ligt boven de spaarquote ( 2.4% ).
Winst versus markt: De winst van NEU ( 4.6% per jaar) zal naar verwachting langzamer groeien dan de markt Australian ( 12.2% per jaar).
Hoge groeiwinsten: De winst van NEU zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van NEU ( 3.1% per jaar) zal naar verwachting langzamer groeien dan de markt Australian ( 5.6% per jaar).
Hoge groei-inkomsten: De omzet van NEU ( 3.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen NEU zal naar verwachting over 3 jaar hoog zijn ( 24.2 %)